01 1National Cancer Institute
01 1PSEUDOMONAS EXOTOXIN (RECOMBINANT, NLYSPE38) CONJUGATED MURINE MAB (B3) TO B3 ANTIGEN AND RITUXIMAB [CHIMERIC MOAB (C2B8) (IDEC) TO CD20]
01 1U.S.A
01 1Inactive
01 1Blank
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18615
Submission : 1993-03-22
Status : Inactive
Type : II
20
National Institutes Health National Cancer Institute, based in U.S.A, is a pharmaceutical company.
One of their notable products is PSEUDOMONAS EXOTOXIN (RECOMBINANT, NLYSPE38) CONJUGATED MURINE MAB (B3) TO B3 ANTIGEN AND RITUXIMAB [CHIMERIC MOAB (C2B8) (IDEC) TO CD20], with a corresponding US DMF Number 18615.
Remarkably, this DMF maintains an Inactive status since its submission on March 22, 1993, highlighting commitment to regulatory compliance.
